Table 4. Absolute Change From Baseline PASI at 6 and 12 Months.
| Variable | Etanercept | Adalimumab | Ustekinumab | |||
|---|---|---|---|---|---|---|
| 6 Months | 12 Months | 6 Months | 12 Months | 6 Months | 12 Months | |
| Absolute change in PASI from baseline, median (IQR)a | ||||||
| Eligible | −10.4 (−13.7 to −6.9) |
−10.8 (−14.3 to −7.3) |
−14.6 (−19.5 to −11.2) |
−14.6 (−19.5 to −11.1) |
−14.5 (−18 to −11.3) |
−14.4 (−18.3 to −11) |
| Ineligible | −9.4 (−13.2 to −5.5) |
−10.5 (−15.7 to −7.2) |
−10.6 (−16.9 to −6.6) |
−9.9 (−15.5 to −8.5) |
−11.2 (−18.3 to −6.4) |
−11.1 (−17.9 to −7.7) |
| i-PASI | −2.4 (−5.5 to 0) |
−2.8 (−4.5 to −1) |
−7.4 (−9.8 to −3.6) |
−7.3 (−9.6 to −3.6) |
−7.6 (−9.6 to −2.6) |
−7.8 (−9.8 to −4.6) |
| Unadjusted linear regression of absolute change in PASI; β-coefficient (95% CI)b | ||||||
| Ineligible | 0.7 (−0.8 to 2.2) |
−0.3 (−1.8 to 1.1) |
3.3 (1.0 to 5.5) |
2.7 (0.5 to 4.9) |
2.0 (0.3 to 3.8) |
1.8 (0.1 to 3.5) |
| i-PASI | 8.8 (6.8 to 10.8) |
8.3 (6.4 to 10.2) |
9.5 (8.6 to 10.4) |
9.1 (8.3 to 10.0) |
8.6 (7.0 to 10.2) |
8.5 (6.9 to 10.1) |
| Adjusted linear regression of absolute change in PASI; β-coefficient (95% CI)b | ||||||
| Ineligible | 0.6 (−1.2 to 2.5) |
0.1 (−1.7 to 1.8) |
3.1 (0.8 to 5.5) |
2.9 (0.6 to 5.1) |
0.5 (−1.4 to 2.5) |
0.5 (−1.5 to 2.4) |
| i-PASI | 8.8 (6.8 to 10.9) |
8.3 (6.3 to 10.3) |
9.4 (8.5 to 10.3) |
9.1 (8.3 to 10.0) |
8.7 (7.0 to 10.4) |
8.5 (6.9 to 10.2) |
| Age ≥70 y | −0.1 (−3.7 to 3.5) |
0.5 (−3.0 to 3.9) |
2.3 (−0.5 to 5.2) |
0.5 (−2.3 to 3.3) |
1.0 (−2.5 to 4.5) |
0.9 (−2.5 to 4.4) |
| BMI | 0.1 (0.0 to 0.2) |
0 (−0.1 to 0.1) |
0.1 (0.0 to 0.1) |
0.1 (0.0 to 0.2) |
0.1 (−0.0 to 0.2) |
0.1 (−0.0 to 0.2) |
| ≥3 Comorbidities | 0 (−2.7 to 2.7) |
−0.3 (−2.9 to 2.3) |
0.3 (−1.5 to 2.1) |
0.1 (−1.7 to 1.8) |
3.2 (0.5 to 5.9) |
3.2 (0.6 to 5.9) |
| Prevalent PsA | 0.7 (−0.8 to 2.2) |
0.5 (−1.0 to 1.9) |
−0.5 (−1.5 to 0.5) |
0.1 (−0.9 to 1.0) |
0.6 (−1.1 to 2.3) |
0.4 (−1.3 to 2.1) |
| Male sex | −0.9 (−2.2 to 0.4) |
−1.3 (−2.5 to −0.0) |
−1.0 (−1.9 to −0.2) |
−0.9 (−1.8 to −0.1) |
−0.8 (−2.2 to 0.7) |
0.1 (−1.3 to 1.5) |
| Ever smoked | 0.2 (−1.1 to 1.5) |
−0.3 (−1.5 to 0.9) |
−0.3 (−1.1 to 0.6) |
−0.1 (−0.9 to 0.8) |
0 (−1.4 to 1.5) |
−0.2 (−1.6 to 1.3) |
Abbreviations: i-PASI, insufficient baseline Psoriasis Area and Severity Index; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); PsA, psoriatic arthritis.
a
Two-sample t test: eligible group vs ineligible or i-PASI group.
b
Eligible group as reference category.